Upstream Bio, Inc.

Compare

146 Followers

UPB Stock Chart & Stats

$24.19

-$0.08(-0.49%)

At close: Jan 08 4:00 PM EST

$24.19

-$0.08(-0.49%)

Day’s Range― - ―

52-Week Range$5.14 - $29.46

Previous CloseN/A

Volume32.37K

Average Volume (3M)433.44K

Market Cap

$1.13B

Enterprise Value$198.38M

Total Cash (Recent Filing)$393.58M

Total Debt (Recent Filing)$1.56M

Price to Earnings (P/E)―

Beta0.68

Next Earnings

Nov 06, 2025

EPS Estimate

-0.76

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.74

Shares Outstanding53,909,428

10 Day Avg. Volume348,822

30 Day Avg. Volume433,444

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.18

Enterprise Value/Revenue72.85

Enterprise Value/Gross Profit72.85

Enterprise Value/Ebitda-1.63

Forecast

1Y Price Target

$61.00

Price Target Upside152.17% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessFollowing encouraging positive results from the Phase II VIBRANT study in CRSwNP patients, the stock is considered attractive ahead of Phase II results in asthma, expected in the first quarter of 2026.

Differentiated Biologic TreatmentUPB's TSLP-receptor inhibitor, verekitug, offers a differentiated, and now de-risked biologic treatment option for I&I respiratory diseases, which represents a rapidly growing multi-billion dollar market.

Improved Dosing ScheduleVerekitug offers robust efficacy with a much improved dosing schedule by targeting the receptor, compared to other biologics for severe asthma.

Bears Say

Operational ExpensesUpstream Bio reported Q2 OpEx of ($45M), above the estimated ($36M).

Risks In DevelopmentRisks to the rating and price target include safety, clinical, regulatory, competition, and financing inherent to all development stage biotechs including UPB.

Upstream Bio, Inc. News

Upstream Bio initiated with a Buy at Truist

Truist initiated coverage of Upstream Bio (UPB) with a Buy rating and $47 price target Verekitug offers similarly...

17d ago

UPB

Upstream Bio management to meet with Piper Sandler

Meeting to be held in Connecticut on October 15 and in New York on October 16 hosted by...

24d ago

UPB

Upstream Bio’s Promising Trials and Strategic Outlook Drive Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on...

17h ago

UPB

Upstream Bio’s COPD Study: A Potential Game-Changer for Investors

Upstream Bio, Inc. (($UPB)) announced an update on their ongoing clinical study. Upstream Bio, Inc. (UPB) is conducting...

3d ago

UPB

Upstream Bio’s Verekitug Study: A Potential Game-Changer for Severe Asthma Treatment

Upstream Bio, Inc. (($UPB)) announced an update on their ongoing clinical study. Upstream Bio, Inc. is conducting a...

3d ago

UPB

Upstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease

Upstream Bio (UPB) presented structural and mechanistic data showing verekitug’s potent pharmacodynamic activity through its approach of targeting...

1M ago

UPB

Positive Phase 2 Results for Upstream Bio’s Verekitug Boost Stock Potential

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on UPB stock, giving a Buy rating yesterday....

2M ago

UPB

Positive Buy Rating for Upstream Bio, Inc. Driven by Promising Clinical Trial Results for Verekitug

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on...

2M ago

UPB

Upstream Bio Announces Positive Phase 2 Trial Results

Upstream Bio, Inc. ( ($UPB) ) has provided an announcement. On September 2, 2025, Upstream Bio announced positive...

2M ago

UPB

Upstream Bio’s verekitug meets endpoints in Phase 2 rhinosinusitis trial

Upstream Bio (UPB) announced positive top-line results from the Phase 2 VIBRANT trial evaluating verekitug in participants with...

2M ago

UPB

Upstream Bio, Inc. Reports Increased R&D Investments

Upstream Bio, Inc. ( ($UPB) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

UPB

Optimistic Buy Rating for Upstream Bio, Inc. Driven by Promising Lead Asset and Strong Execution

TD Cowen analyst Yaron Werber has maintained their bullish stance on UPB stock, giving a Buy rating today....

3M ago

UPB

Positive Outlook for Upstream Bio, Inc. Driven by Promising Clinical Trial Developments

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on...

3M ago

UPB

Upstream Bio reports Q2 revenue $937k, consensus $317k

“We continued to build momentum this quarter with strong execution across our clinical development programs for verekitug in...

3M ago

UPB

UPB FAQ

What was Upstream Bio, Inc.’s price range in the past 12 months?

Upstream Bio, Inc. lowest stock price was $5.14 and its highest was $29.46 in the past 12 months.

What is Upstream Bio, Inc.’s market cap?

Upstream Bio, Inc.’s market cap is $1.13B.

When is Upstream Bio, Inc.’s upcoming earnings report date?

Upstream Bio, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 6 days.

How were Upstream Bio, Inc.’s earnings last quarter?

Upstream Bio, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.61 by -$0.13.

Is Upstream Bio, Inc. overvalued?

According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Upstream Bio, Inc. pay dividends?

Upstream Bio, Inc. does not currently pay dividends.

What is Upstream Bio, Inc.’s EPS estimate?

Upstream Bio, Inc.’s EPS estimate is -0.76.

How many shares outstanding does Upstream Bio, Inc. have?

Upstream Bio, Inc. has 53,909,428 shares outstanding.

What happened to Upstream Bio, Inc.’s price movement after its last earnings report?

Upstream Bio, Inc. reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.61. Following the earnings report the stock price went up 7.871%.

Which hedge fund is a major shareholder of Upstream Bio, Inc.?

Currently, no hedge funds are holding shares in UPB

Upstream Bio, Inc. Stock Smart Score

Outperform

Company Description

Upstream Bio, Inc.

Upstream Bio, Inc. (UPB) is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company operates primarily in the biopharmaceutical sector, specializing in the research and development of novel treatments for various diseases, particularly in the fields of oncology and autoimmune disorders. Upstream Bio aims to leverage its proprietary technology platform to advance its pipeline of drug candidates, ultimately seeking to improve patient outcomes through targeted therapies.

Upstream Bio, Inc. (UPB) Earnings & Revenues

Historic Earnings Reports

UPB Stock 12 Month Forecast

Average Price Target

$61.00

▲(152.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","76":"$76","22.75":"$22.8","40.5":"$40.5","58.25":"$58.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$47.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,22.75,40.5,58.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.63,22.966153846153844,27.302307692307693,31.63846153846154,35.97461538461539,40.31076923076924,44.64692307692308,48.98307692307692,53.31923076923077,57.65538461538462,61.99153846153847,66.32769230769232,70.66384615384617,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.63,21.889230769230767,25.14846153846154,28.407692307692308,31.666923076923077,34.926153846153845,38.18538461538462,41.44461538461539,44.70384615384616,47.963076923076926,51.222307692307695,54.48153846153846,57.74076923076923,{"y":61,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.63,20.81230769230769,22.994615384615383,25.176923076923075,27.35923076923077,29.541538461538458,31.723846153846154,33.90615384615384,36.08846153846154,38.27076923076923,40.45307692307692,42.63538461538461,44.81769230769231,{"y":47,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.38,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.76,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >